Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology.
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to:
- Demonstrate target engagement for novel therapeutics
Biomarkers that can serve as direct measures of target engagement for novel drugs in clinical development. High priority will be given to projects advancing biomarkers that can be used as specific companion biomarkers for therapies currently in the development pipeline. Identification of such therapies strengthens an application.
- Detect signs of disease earlier and monitor progression
Programs developing sensitive biomarkers that can detect disease earlier than currently available biomarkers. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer’s disease. We also seek prognostic markers that can predict rates of cognitive decline.
- More accurately diagnose and distinguish between dementia subtypes
Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes and proteinopathies. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.
Funding is for one year with potential for follow-on funding. Multi-year proposals can be considered.
The award is up to $600,000 based on stage and scope of research. Larger amounts will be considered for PET ligand development for regulatory or clinical work. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Deadline for LoI: 5 February 2024